Paul M. Barr

基本信息

Career Trajectory

Bio

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

Research Interests

Papers共 340 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Treatment of Relapsed/Refractory CLL Patients with PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance

Jennifer E Bruno,Christine A Herne,Andrea M Baran,Karl R VanDerMeid,Paul M Barr,Alyssa R Williams,Sally A Quataert, Tim R Mosmann,Clive S Zent,Charles C Chu

American journal of hematologyno. 3 (2025): 523-526

Cited0Views0WOSBibtex

Ready, AIM, Stop: Ibrutinib Plus Venetoclax in MCL

Danielle S. Wallace,Paul M. Barr

Bloodno. 8 (2024): 800-802

Cited0Views0WOSBibtex

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (idelar) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jeff P. Sharman,Talha Munir,Sebastian Grosicki,Lindsey Roeker,John M. Burke,Christine I Chen,Norbert Grzasko,George Follows, Zoltán Mátrai,Alessandro Sanna, Shuhua Yi,Ru Feng, Vu Minh Hua, Jadwiga Holodja,Wojciech Jurczak, Matthias Ritgen,Lu-Gui Qiu, Francesc Bosch,Catherine C. Coombs,Katherine Bao,Vishalkumar Patel, Bin Liu, Livia Compte,Ananya Guntur, Ying (Denise) Wang,Marisa Hill, Ching,Paolo Ghia,Paul M Barr

Bloodno. Supplement 1 (2024): 886-886

Cited0Views0Bibtex

First‐line Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia is Associated with Overall Survival Rates Similar to Those of an Age‐matched General Population: A Pooled Post Hoc Analysis

Paolo Ghia,Carolyn Owen,John N Allan,Jacqueline C Barrientos,Paul M Barr, Chunxue Shi,Anita Szoke, Christopher Abbazio,Gabriel S Krigsfeld,Jan A Burger

HemaSphereno. 5 (2024)

Cited1Views0WOSBibtex

Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

Jan A. Burger,Neil E. Kay,John N. Allan,Paul M Barr,Jacqueline C. Barrientos,Carolyn Owen,Victoria Wang, Hsin-Hui Huang,Lynne Neumayr, Christopher Abbazio,Gabriel S. Krigsfeld, Sneh Mody,Paolo Ghia,Tait D. Shanafelt

Bloodno. Supplement 1 (2024): 4615-4615

Cited0Views0Bibtex

Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey

Deborah M. Stephens, Chris Stewart,Liza Avruch,Catherine C. Coombs,Alexey Danilov,Brian T. Hill,Mazyar Shadman,Alina S. Gerrie,Christopher E. Jensen,Marc Hoffmann,Allison M. Winter,Daniel A. Ermann,Paul M. Barr,Susan M. O'Brien,Brian Koffman,John C. Byrd

BLOOD（2024）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Professor

Papers共 340 篇Author StatisticsCo-AuthorSimilar Experts